Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 6/20 | 0.48 |
| ▸ | MLYCD | O95822 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.45 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.43 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.43 |
| ▸ | HRH1 | P35367 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.42 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.42 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083042 | 0.83 | DRD2 (0.49) | DRD2MLYCDSIGMAR1SCN9ADRD4 | |
| SCHEMBL12049805 | 0.81 | MLYCD (0.54) | DRD2MLYCDSCN9A | |
| SCHEMBL5619996 | 0.80 | DRD2 (0.51) | DRD2MLYCDSIGMAR1SCN9ADRD4 | |
| SCHEMBL4093532 | 0.80 | DRD2 (0.61) | DRD2 | |
| SCHEMBL12026476 | 0.78 | MLYCD (0.52) | DRD2MLYCDSCN9AKCNH2 | |
| SCHEMBL6198200 | 0.74 | SLC18A3 (0.63) | DRD2SIGMAR1CARM1PRMT6 | |
| SCHEMBL4827439 | 0.72 | DRD3 (0.75) | DRD2SIGMAR1DRD3 | |
| SCHEMBL16835114 | 0.72 | DRD2 (0.67) | DRD2MLYCDSCN9ADRD4KCNH2 | |
| SCHEMBL23993213 | 0.71 | MLYCD (0.48) | DRD2MLYCDSCN9AKCNH2DRD3 | |
| SCHEMBL4827438 | 0.71 | DRD2 (0.63) | DRD2SIGMAR1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2009-03-05 | — | — | US | disclosed |
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | 7TM PHARMA A/S (DK) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062317-A1 | MEDICINAL USE OF RECEPTOR LIGANDS | MCHR1, MCHR2, MC1R | DRD2 606/4885MLYCD 536/4885SIGMAR1 93/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.